LYRA Quote, Financials, Valuation and Earnings

Electromed has a net margin of -4670.49% compared to Lyra Therapeutics's net margin of 12.06%. Lyra Therapeutics's return on equity of -275.07% beat Electromed's return on equity of 16.57%.

Lyra Therapeutics has a consensus price target of $23.00, signalling upside risk potential of 171.23%. On the other hand Electromed has an analysts' consensus of $33.50 which suggests that it could grow by 83.66%. Given that Lyra Therapeutics has higher upside potential than Electromed, analysts believe Lyra Therapeutics is more attractive than Electromed.

Lyra Therapeutics has a beta of 0.242, which suggesting that the stock is 75.839% less volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Lyra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyra Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Lyra Therapeutics quarterly revenues are $183K, which are smaller than Electromed quarterly revenues of $15.7M. Lyra Therapeutics's net income of -$8.5M is lower than Electromed's net income of $1.9M. Notably, Lyra Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 23.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyra Therapeutics is 9.38x versus 2.66x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -4670.49% compared to Lyra Therapeutics's net margin of -35.24%. Lyra Therapeutics's return on equity of -275.07% beat Myomo's return on equity of -38.11%.

Lyra Therapeutics has a consensus price target of $23.00, signalling upside risk potential of 171.23%. On the other hand Myomo has an analysts' consensus of $8.70 which suggests that it could grow by 335%. Given that Myomo has higher upside potential than Lyra Therapeutics, analysts believe Myomo is more attractive than Lyra Therapeutics.

Lyra Therapeutics has a beta of 0.242, which suggesting that the stock is 75.839% less volatile than S&P 500. In comparison Myomo has a beta of 1.389, suggesting its more volatile than the S&P 500 by 38.863%.

Lyra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyra Therapeutics pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Lyra Therapeutics quarterly revenues are $183K, which are smaller than Myomo quarterly revenues of $9.8M. Lyra Therapeutics's net income of -$8.5M is lower than Myomo's net income of -$3.5M. Notably, Lyra Therapeutics's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyra Therapeutics is 9.38x versus 2.02x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -4670.49% compared to Lyra Therapeutics's net margin of -2201.34%. Lyra Therapeutics's return on equity of -275.07% beat VolitionRX's return on equity of --.

Lyra Therapeutics has a consensus price target of $23.00, signalling upside risk potential of 171.23%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 355.11%. Given that VolitionRX has higher upside potential than Lyra Therapeutics, analysts believe VolitionRX is more attractive than Lyra Therapeutics.

Lyra Therapeutics has a beta of 0.242, which suggesting that the stock is 75.839% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

Lyra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyra Therapeutics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Lyra Therapeutics quarterly revenues are $183K, which are smaller than VolitionRX quarterly revenues of $246.4K. Lyra Therapeutics's net income of -$8.5M is lower than VolitionRX's net income of -$5.4M. Notably, Lyra Therapeutics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyra Therapeutics is 9.38x versus 44.53x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -4670.49% compared to Lyra Therapeutics's net margin of 0.18%. Lyra Therapeutics's return on equity of -275.07% beat Xtant Medical Holdings's return on equity of -26.62%.

Lyra Therapeutics has a consensus price target of $23.00, signalling upside risk potential of 171.23%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 182.3%. Given that Xtant Medical Holdings has higher upside potential than Lyra Therapeutics, analysts believe Xtant Medical Holdings is more attractive than Lyra Therapeutics.

Lyra Therapeutics has a beta of 0.242, which suggesting that the stock is 75.839% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

Lyra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyra Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Lyra Therapeutics quarterly revenues are $183K, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Lyra Therapeutics's net income of -$8.5M is lower than Xtant Medical Holdings's net income of $58K. Notably, Lyra Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyra Therapeutics is 9.38x versus 0.69x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.